5/9/2025

Janusmed sex and gender

Janusmed sex and gender – osimertinib

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
C C
C C

Osimertinib

Osimertinib

Class : C

Show all info

Print

Contact us

  1. Vera Regitz-Zagrosek. Sex and Gender Differences in Pharmacology. Springer-Verlag Berlin Heidelberg; 2012.

  2. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626-38.

  3. Socialstyrelsen. Cancer i siffror 2023. Socialstyrelsen [www]. [updated 2024-04-26, cited 2024-01-31].

  4. Tagrisso (osimertinib). Summary of Products Characteristics. European Medicines Agency (EMA) [updated 2024-02-08, cited 2024-04-26]

  5. van Veelen A, Gulikers J, Hendriks LEL, Dursun S, Ippel J, Smit EF et al. Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer: The OSIBOOST trial. Lung Cancer. 2022;171:97-102.

  6. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378(2):113-125.

  7. Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017;376(7):629-640.

  8. Huang L, Huang H, Zhou XP, Liu JF, Li CR, Fang M et al. Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer: A meta-analysis. Medicine (Baltimore). 2019;98(43):e17705.

  9. FDA Adverse Event Reporting System (FAERS) Public Dashboard. Food and Drug Administration (FDA) [www]. [updated 2023-12-07, cited 2024-04-26].

  10. Li Z, Zou W, Yuan J, Zhong Y, Fu Z. Gender differences in adverse events related to Osimertinib: a real-world pharmacovigilance analysis of FDA adverse event reporting system. Expert Opin Drug Saf. 2024;23(6):763-770.

  11. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2023 [cited 2024-03-06.]

  1. Vera Regitz-Zagrosek. Sex and Gender Differences in Pharmacology. Springer-Verlag Berlin Heidelberg; 2012.
  2. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626-38.
  3. Socialstyrelsen. Cancer i siffror 2023. Socialstyrelsen [www]. [updated 2024-04-26, cited 2024-01-31].
  4. Tagrisso (osimertinib). Summary of Products Characteristics. European Medicines Agency (EMA) [updated 2024-02-08, cited 2024-04-26]
  5. van Veelen A, Gulikers J, Hendriks LEL, Dursun S, Ippel J, Smit EF et al. Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer: The OSIBOOST trial. Lung Cancer. 2022;171:97-102.
  6. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378(2):113-125.
  7. Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017;376(7):629-640.
  8. Huang L, Huang H, Zhou XP, Liu JF, Li CR, Fang M et al. Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer: A meta-analysis. Medicine (Baltimore). 2019;98(43):e17705.
  9. FDA Adverse Event Reporting System (FAERS) Public Dashboard. Food and Drug Administration (FDA) [www]. [updated 2023-12-07, cited 2024-04-26].
  10. Li Z, Zou W, Yuan J, Zhong Y, Fu Z. Gender differences in adverse events related to Osimertinib: a real-world pharmacovigilance analysis of FDA adverse event reporting system. Expert Opin Drug Saf. 2024;23(6):763-770.
  11. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2023 [cited 2024-03-06.]